Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Dexamethasone + Lenalidomide + Linvoseltamab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dexamethasone | Adexone | Desametasone | ||
Lenalidomide | Revlimid | IMiD-1 | Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov). | |
Linvoseltamab | REGN5458|REGN-5458|REGN 5458|Anti-BCMA/CD3 BiTE | CD3 Antibody 99 TNFRSF17 Antibody 20 | Linvoseltamab (REGN5458) is a bispecific antibody that binds to TNFRSF17 (BCMA) and CD3 with potential antitumor activity (Blood (2019) 134 (Supplement_1): 3176). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05137054 | Phase I | Bortezomib + Dexamethasone + Linvoseltamab Carfilzomib + Dexamethasone + Linvoseltamab Dexamethasone + Lenalidomide + Linvoseltamab Daratumumab + Dexamethasone + Linvoseltamab | REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With Relapsed/Refractory Multiple Myeloma | Recruiting | USA | GRC | FRA | ESP | 0 |